Henry Schein (HSIC) Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HSIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HSIC, but not buy additional shares or sell existing shares.
View HSIC analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 12 month target prices for Henry Schein's stock. Their HSIC share price forecasts range from $69.00 to $97.00. On average, they expect the company's stock price to reach $84.00 in the next twelve months. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for HSIC or view top-rated stocks among Wall Street analysts.

Henry Schein's stock was trading at $79.87 at the beginning of 2023. Since then, HSIC stock has decreased by 8.5% and is now trading at $73.11.
View the best growth stocks for 2023 here.

Henry Schein saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 2,160,000 shares, a decline of 26.8% from the August 15th total of 2,950,000 shares. Based on an average daily volume of 857,800 shares, the short-interest ratio is currently 2.5 days. Approximately 1.7% of the shares of the company are sold short.
View Henry Schein's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our HSIC earnings forecast.

Henry Schein, Inc. (NASDAQ:HSIC) announced its quarterly earnings data on Monday, August, 7th. The company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The business earned $3.10 billion during the quarter, compared to the consensus estimate of $3.13 billion. Henry Schein had a net margin of 3.64% and a trailing twelve-month return on equity of 15.76%. The company's quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.16 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Henry Schein (NASDAQ:HSIC) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), American CenturyFocused Large Cap Value ETF (FLV), Invesco S&P 500 Equal Weight Health Care ETF (RSPH), Invesco S&P 500 Equal Weight Health Care ETF (RYH), First Trust Health Care AlphaDEX Fund (FXH), Invesco ESG NASDAQ Next Gen 100 ETF (QQJG), Invesco NASDAQ Next Gen 100 ETF (QQQJ) and First Trust Active Factor Mid Cap ETF (AFMC).

Shares of Henry Schein split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were issued to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Henry Schein announced that its Board of Directors has authorized a stock buyback plan on Thursday, August 18th 2022, which permits the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's leadership believes its shares are undervalued.

Henry Schein issued an update on its FY 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share guidance of $5.18-$5.35 for the period, compared to the consensus EPS estimate of $5.27. The company issued revenue guidance of $12.77 billion-$13.03 billion, compared to the consensus revenue estimate of $12.83 billion.

451 employees have rated Henry Schein Chief Executive Officer Stanley M. Bergman on Glassdoor.com. Stanley M. Bergman has an approval rating of 94% among the company's employees. This puts Stanley M. Bergman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), QUALCOMM (QCOM), CVS Health (CVS), Micron Technology (MU) and AT&T (T).

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.61%), Bank Julius Baer & Co. Ltd Zurich (5.14%), State Street Corp (5.16%), JPMorgan Chase & Co. (3.61%), Perpetual Ltd (3.32%) and Longview Partners Guernsey LTD (2.49%). Insiders that own company stock include Bradford C Connett, David B Brous Jr, Deborah Derby, Gerald A Benjamin, James P Breslawski, James P Breslawski, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael S Ettinger, Philip A Laskawy, Scott Philip Serota, Stanley M Bergman, Steven Paladino and Walter Siegel.
View institutional ownership trends.

Shares of HSIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HSIC stock can currently be purchased for approximately $73.11.

Henry Schein (NASDAQ:HSIC) has a market capitalization of $9.55 billion and generates $12.60 billion in revenue each year. The company earns $538 million in net income (profit) each year or $3.40 on an earnings per share basis.

The company employs 22,000 workers across the globe.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The official website for the company is www.henryschein.com. The company can be reached via phone at (631) 843-5500, via email at steven.paladino@henryschein.com, or via fax at 631-843-5541.